PT1185272E - Utilizacao nova de 1-¬4-(5-cianoindolo-3-il)butil|-4-(2-carbamoilbenzofurano-5-il) piperazina e seus sais fisiologicamente aceitaveis - Google Patents

Utilizacao nova de 1-¬4-(5-cianoindolo-3-il)butil|-4-(2-carbamoilbenzofurano-5-il) piperazina e seus sais fisiologicamente aceitaveis

Info

Publication number
PT1185272E
PT1185272E PT00935031T PT00935031T PT1185272E PT 1185272 E PT1185272 E PT 1185272E PT 00935031 T PT00935031 T PT 00935031T PT 00935031 T PT00935031 T PT 00935031T PT 1185272 E PT1185272 E PT 1185272E
Authority
PT
Portugal
Prior art keywords
cyanoindolo
carbamoylbenzofurane
piperazine
butyl
new use
Prior art date
Application number
PT00935031T
Other languages
English (en)
Portuguese (pt)
Inventor
Gerd Bartoszyk
Christoph Seyfri
Henning Bottcher
Christoph Van Amsterdam
Ewen Sedman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1185272(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT1185272E publication Critical patent/PT1185272E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT00935031T 1999-05-27 2000-05-16 Utilizacao nova de 1-¬4-(5-cianoindolo-3-il)butil|-4-(2-carbamoilbenzofurano-5-il) piperazina e seus sais fisiologicamente aceitaveis PT1185272E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27

Publications (1)

Publication Number Publication Date
PT1185272E true PT1185272E (pt) 2004-08-31

Family

ID=8238153

Family Applications (3)

Application Number Title Priority Date Filing Date
PT06017231T PT1736158E (pt) 1999-05-27 2000-05-16 Nova utilização de 1-[4-(5-cianoindol-3-il)butil]-4-(2- carbamoil-benzofuran-5-il)-piperazina e seus sais fisiologicamente aceitáveis
PT04001441T PT1410800E (pt) 1999-05-27 2000-05-16 Utilização de 1- ( 4-(5-cianoindol-3-il ) butil )-4-(2-carbamoilbenzofuran-5-il )-piperazina e seus sais fisiologicamente aceitáveis
PT00935031T PT1185272E (pt) 1999-05-27 2000-05-16 Utilizacao nova de 1-¬4-(5-cianoindolo-3-il)butil|-4-(2-carbamoilbenzofurano-5-il) piperazina e seus sais fisiologicamente aceitaveis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT06017231T PT1736158E (pt) 1999-05-27 2000-05-16 Nova utilização de 1-[4-(5-cianoindol-3-il)butil]-4-(2- carbamoil-benzofuran-5-il)-piperazina e seus sais fisiologicamente aceitáveis
PT04001441T PT1410800E (pt) 1999-05-27 2000-05-16 Utilização de 1- ( 4-(5-cianoindol-3-il ) butil )-4-(2-carbamoilbenzofuran-5-il )-piperazina e seus sais fisiologicamente aceitáveis

Country Status (31)

Country Link
US (4) US6900212B1 (enExample)
EP (3) EP1410800B1 (enExample)
JP (2) JP4884588B2 (enExample)
KR (1) KR100683367B1 (enExample)
CN (3) CN1198618C (enExample)
AR (1) AR024112A1 (enExample)
AT (3) ATE263564T1 (enExample)
AU (1) AU771778B2 (enExample)
BR (1) BR0010948A (enExample)
CA (3) CA2615271C (enExample)
CY (2) CY1105750T1 (enExample)
CZ (1) CZ295623B6 (enExample)
DE (3) DE60030338T2 (enExample)
DK (3) DK1736158T3 (enExample)
ES (3) ES2330774T3 (enExample)
HK (1) HK1048444B (enExample)
HU (1) HU229059B1 (enExample)
IL (2) IL146707A0 (enExample)
MX (1) MXPA01012172A (enExample)
MY (1) MY135627A (enExample)
NO (2) NO322120B1 (enExample)
PL (3) PL199650B1 (enExample)
PT (3) PT1736158E (enExample)
RU (1) RU2237477C2 (enExample)
SI (2) SI1410800T1 (enExample)
SK (1) SK287851B6 (enExample)
TR (1) TR200103361T2 (enExample)
TW (1) TW518218B (enExample)
UA (1) UA74337C2 (enExample)
WO (1) WO2000072832A2 (enExample)
ZA (1) ZA200110485B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
WO2005094896A2 (en) * 2004-03-26 2005-10-13 Baylor University Targeted serotonin reuptake inhibitors
CA2651663A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
TW200932235A (en) 2007-12-20 2009-08-01 Astrazeneca Ab Carbamoyl compounds as DGAT1 inhibitors
RU2011152517A (ru) 2009-06-19 2013-07-27 Астразенека Аб Пиразинкарбоксамиды в качестве ингибиторов dgat1
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
CA2779442A1 (en) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012131706A1 (en) 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
US9382233B2 (en) 2012-06-13 2016-07-05 Apotex Inc. Forms of vilazodone and processes for the preparation thereof
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
CN107949379A (zh) * 2015-05-22 2018-04-20 维斯塔津治疗公司 L‑4‑氯代犬尿氨酸的治疗用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612564A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
NO324230B1 (no) 2007-09-10
PT1736158E (pt) 2009-11-11
ZA200110485B (en) 2003-06-30
CA2615271A1 (en) 2000-12-07
CA2694866A1 (en) 2000-12-07
UA74337C2 (uk) 2005-12-15
WO2000072832A2 (en) 2000-12-07
HUP0201275A3 (en) 2004-04-28
HU229059B1 (en) 2013-07-29
AR024112A1 (es) 2002-09-04
EP1410800B1 (en) 2006-08-23
NO20015746D0 (no) 2001-11-26
SI1410800T1 (sl) 2007-02-28
CZ20014226A3 (cs) 2002-03-13
WO2000072832A3 (en) 2001-12-20
SK16462001A3 (sk) 2002-02-05
BR0010948A (pt) 2002-04-23
NO322120B1 (no) 2006-08-14
RU2237477C2 (ru) 2004-10-10
ATE438399T1 (de) 2009-08-15
EP1185272B1 (en) 2004-04-07
PL352373A1 (en) 2003-08-25
MY135627A (en) 2008-05-30
JP4884588B2 (ja) 2012-02-29
KR100683367B1 (ko) 2007-02-15
EP1410800A1 (en) 2004-04-21
US7642261B2 (en) 2010-01-05
CA2372668C (en) 2009-11-03
ATE337008T1 (de) 2006-09-15
DK1736158T3 (da) 2009-11-02
PL199516B1 (pl) 2008-09-30
SI1185272T1 (en) 2004-12-31
HK1048444A1 (en) 2003-04-04
CY1109472T1 (el) 2012-05-23
ES2330774T3 (es) 2009-12-15
PL199650B1 (pl) 2008-10-31
CN1198618C (zh) 2005-04-27
EP1736158A3 (en) 2007-01-03
ES2271707T3 (es) 2007-04-16
IL146707A (en) 2007-06-03
CZ295623B6 (cs) 2005-09-14
US20080119484A1 (en) 2008-05-22
EP1736158B1 (en) 2009-08-05
ATE263564T1 (de) 2004-04-15
PL200490B1 (pl) 2009-01-30
TR200103361T2 (tr) 2002-05-21
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
TW518218B (en) 2003-01-21
JP2003500441A (ja) 2003-01-07
CN1361692A (zh) 2002-07-31
CY1105750T1 (el) 2010-12-22
AU771778B2 (en) 2004-04-01
MXPA01012172A (es) 2002-07-22
DE60009697T2 (de) 2005-04-14
HUP0201275A2 (en) 2002-08-28
CN101869565A (zh) 2010-10-27
DE60042710D1 (de) 2009-09-17
JP2011148799A (ja) 2011-08-04
NO20061562L (no) 2001-11-26
NO20015746L (no) 2001-11-26
US20100063062A1 (en) 2010-03-11
EP1736158A2 (en) 2006-12-27
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
DE60030338T2 (de) 2007-08-16
HK1048444B (zh) 2005-12-09
DK1410800T3 (da) 2006-12-27
DE60009697D1 (de) 2004-05-13
CA2372668A1 (en) 2000-12-07
AU5066300A (en) 2000-12-18
US7371756B2 (en) 2008-05-13
IL146707A0 (en) 2002-07-25
KR20020008847A (ko) 2002-01-31
PT1410800E (pt) 2007-01-31
CN1679577A (zh) 2005-10-12
SK287851B6 (sk) 2012-01-04
DE60030338D1 (de) 2006-10-05
CA2615271C (en) 2011-02-15
DK1185272T3 (da) 2004-08-09

Similar Documents

Publication Publication Date Title
PT1185272E (pt) Utilizacao nova de 1-¬4-(5-cianoindolo-3-il)butil|-4-(2-carbamoilbenzofurano-5-il) piperazina e seus sais fisiologicamente aceitaveis
DK1267880T3 (da) Entecavir-formulering med lav dosis og anvendelse deraf
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO990551D0 (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
NO20013538L (no) Piperidin, tetrahydropyridin og piperazinderivater, deres fremstilling og anvendelse
NO20015004L (no) Vandig desinfiseringsmiddel og sammensetning for vask av harde overflater samt fremgangsmåte for anvendelse derav
HUP0301391A3 (en) Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
DK1283838T3 (da) Piperazin- og piperidinforbindelser
EE200100498A (et) 1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
ATE275390T1 (de) Verwendung von kationischen zubereitungen
AU3022201A (en) Novel use of (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)- chromane and its physiologically aceptable salts
DE50103099D1 (de) Verwendung von kationischen Zubereitungen
DE60221331D1 (de) Verwendung von 4-Ethyloctanal in Riech- und Geschmackzusammensetzungen
PT1131308E (pt) Novos compostos de piperazina e piperidina
NO20021986D0 (no) Natrium-2-(4,6-dimetyl-pyrimidin-2-yloksy)-3-(2-(3,4- dimetoksyfenyl)etoksy)-3,3-difenylpropionat og anvendelse deravsom endothelin-antagonist
ATA182699A (de) Verwendung von aloe oder aloe-extrakten
ATE319448T1 (de) Therapeutische zusammensetzung von amlodipin und benazepril
IL122975A0 (en) Use of 1-[6-chloro-5- (trifluoromethyl)-2-pyridinyl] piperazine
SE0004405D0 (sv) New composition and use
DK1127274T3 (da) Detektor og deres anvendelse